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Usability testing is recognized as an effective means to improve the usability of medical devices and pre-
vent harm for patients and users. Effectiveness of problem discovery in usability testing strongly depends
on size and representativeness of the sample. We introduce the late control strategy, which is to contin-
uously monitor effectiveness of a study towards a preset target.
A statistical model, the LNBzt model, is presented, supporting the late control strategy. We report on a
case study, where a prototype medical infusion pump underwent a usability test with 34 users. On the
data obtained in this study, the LNBzt model is evaluated and compared against earlier prediction models.
The LNBzt model ﬁts the data much better than previously suggested approaches and improves predic-
tion. We measure the effectiveness of problem identiﬁcation, and observe that it is lower than is sug-
gested by much of the literature. Larger sample sizes seem to be in order. In addition, the testing
process showed high levels of uncertainty and volatility at small to moderate sample sizes, partly due
to users’ individual differences. In reaction, we propose the idiosyncrasy score as a means to obtain rep-
resentative samples. Statistical programs are provided to assist practitioners and researchers in applying
the late control strategy.
 2013 Elsevier Inc. All rights reserved.1. Introduction
Well-designed medical devices of good quality are necessary for
providing safe and effective clinical care for patients. Capturing the
user requirements and incorporating them into the design is essen-
tial. Therefore, the ﬁeld of Human Factors has an important role to
play in the development of medical devices, all the more so be-
cause numerous reports show clear links between hazards and
usability problems [1,2].
The ﬁeld of usability engineering has developed an array of
methods to identify usability problems, most importantly empiri-
cal usability testing. However, the practices for usability testing
have been established for evaluating non-critical systems, such
as commercial websites. A major impact factor for effective usabil-
ity tests is the sample size, but the prevalent recommendations for
usability testing studies may not be adequate for safety critical sys-
tems, such as medical devices. Moreover, due to mathematical
misconceptions [3], prevalent recommendations generally under-
state the adequate sample size. In consequence, a considerablenumber of usability problems can go unnoticed, placing severe
risks on patients and users. In this paper we present a rigorous ap-
proach to sample size estimation, that, in essence, continuously
tracks the completeness of problem discovery.
The presented approach bases on an updated mathematical
model for sample size estimation (previously introduced in [4]).
We applied it in a case study, where the prototype of a medical
infusion pump is tested. First, we measure the observed effective-
ness and compare it to classic models. Next, we examine the reli-
ability of predictions and compare it to the volatility of the
usability testing progress. Finally, we compare the impact of two
professional groups (nurses and anesthesiologists) and extend
the approach to also assist in compiling representative user
samples.
1.1. Usability of medical devices
The report ‘‘To err is human’’ from the Institute of Medicine [41]
greatly increased people’s awareness about the frequency, magni-
tude, complexity, and seriousness of medical accidents. As many as
100,000 deaths or serious injuries each year in the US result from
medical accidents. Similar reports have been issued by other
authorities, e.g. France [42] and the UK [43]. Between 2005 and
2009, the FDA collected approximately 56,000 reports of adverse
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ical devices that deliver ﬂuids into a patient’s body in controlled
amounts [21]. A signiﬁcant number of reported adverse events,
many of them led to injuries and deaths, is due to device use errors.
These are errors in how a medical device is used, rather than a
technical malfunction. It is now widely recognized that poorly de-
signed user interfaces induce errors and operating inefﬁciencies
[44], even when operated by well-trained, competent users.
The recognition of the role of good design has resulted in a
number of studies investigating the usability of medical devices,
most notably infusion pumps [1,2,5–7]. User interfaces of medical
equipment demand a high level of reliability in order to create pre-
requisites for safe and effective equipment operation, installation
and maintenance [8]. Poorly designed human–machine interfaces
in medical equipment increase the risk of human error [1,9], as
well as incidents and accidents in medical care. Medication errors
are estimated to be the major source in those errors that compro-
mise patient safety [10–15]. These, together with other common
problems with infusion pump design, may predispose health care
professionals to commit errors that lead to patient harm [16].
The most common cause in erroneous handling during drug deliv-
ery tasks stems from the fact that operators have to remember (re-
call) everything that was previously entered, as well as detecting
and recovering from errors in confusing and complex program-
ming sequences [1,17]. Not surprisingly, most reported problems
are identiﬁed as originating from lack of feedback during program-
ming, even though interfaces should function as an external men-
tal map (cognitive artifact) in supporting monitoring and decision
making processes [17]. Infusion pumps contain numerous modes
of functioning, and often present poor feedback about the mode
in which they are currently set. Also, buttons are often illogically
placed and marked [6]. Previous research indicated that causes
for programming and monitoring difﬁculties resulted from infu-
sion device complexity (ﬂexibility), hidden behind simpliﬁed
pump interfaces not designed from a human performance and fal-
libility point of view [18]. Users therefore becomemore and more a
victim of clumsy automation [19], loss of situational awareness
and mode confusion, often unrecognized as cause in many of the
problems reported.
1.2. Evaluation of medical devices
That user-interface issues with infusion pumps are widely re-
garded serious, is reﬂected by the FDA’s recent initiative to im-
prove pump safety [21]. In order to assure that use-related
hazards have been adequately controlled, the FDA states that three
central steps are essential [22]:
1. Identify anticipated use-related hazards (derived analyti-
cally, for instance by heuristic analysis) and unanticipated
use-related hazards (derived through formative evalua-
tions, for instance simulated use testing).
2. Develop and apply strategies to mitigate or control use-
related hazards.
3. Demonstrate safe and effective device use through human
factors validation testing (either simulated use validation
testing or clinical validation testing).
The analytical approaches and formative evaluations are com-
plementary, each having unique strengths and weaknesses with
respect to identifying, evaluating, and understanding use-related
hazards early in the design process. Formative evaluations can
demonstrate sufﬁcient use-safety for an infusion pump. Formative
evaluation has its strengths in a focus on critical tasks, challenging
or unusual use scenarios and the follow-up to determine the cause
of task failures. Potential limitations of formative evaluationinclude artiﬁcial testing conditions and limited range of users
and use conditions. Clinical validation testing has its strengths in
realistic testing conditions (e.g., time pressure, distractions, noise,
glare), a broader range of users, and unanticipated use conditions,
but potential limitations include lack of control over use scenarios
and testing conditions.
In reaction to what one could call the ‘‘ergonomic crisis’’,
numerous works have aimed at transferring established concepts
of user-centered design to the domain of medical devices. In partic-
ular, usability evaluation gained attention: Martin et al. review a
number of user-centered methods for requirements analysis and
usability evaluation of medical devices [17]. In their conclusion,
they clearly favor usability testing over expert inspection methods
such as heuristic evaluation and cognitive walkthrough. Liljegren
reports on a survey on the importance of several usability criteria
for medical equipment and found ‘difﬁculty to make errors’ ranked
highest [20]. From a subsequent assessment of several evaluation
methods it was concluded that usability testing is the most effec-
tive evaluation method.
1.3. Effectiveness of usability evaluations
In the current paper, we take the position that measuring and
controlling the effectiveness of formative evaluation, usability test-
ing in particular, is crucial for risk reduction in the development of
medical devices. Undiscovered design faults decrease performance
(e.g., by imposing higher cognitive workload) and raise the proba-
bility of hazard (e.g., mistakes made when inserting or modifying
the dosage), harming peoples’ health. While many studies have ad-
dressed various impact factors on effectiveness of usability evalu-
ation, there is general agreement on one factor: the sample size.
However, Bastien [23] reviews the usability testing method for
medical applications and concludes that the ‘‘question of the num-
ber of users to test is far from being solved and requires further re-
search’’ (p. 20). While the importance of sample size is beyond
doubt, quantifying its impact has seen a long and heated discussion
[24]. Several authors suggested so-called magic numbers [25,26].
Others introduced mathematical models to estimate the required
sample size and a third fraction claims the whole issue practically
irrelevant [27].
A central assumption in this paper is that usability researchers
in the domain of medical devices have at least three good reasons
to strive for effective discovery of usability problems: First, medical
devices are high risk systems: many past incidents have shown
that poor usability can cause use-related hazards and, in conse-
quence cost lives [16]. Second, authorities have acknowledged
the problems and manufacturers are now liable for thorough test-
ing of the devices [28]. And third, medical devices are embedded
devices, with much of the functionality still provided in hardware.
It is well known fact in systems engineering that late ﬁxes of
safety–critical embedded devices are extremely costly [29].
In the following sections we give an overview on possible strat-
egies for sample size managements, as well as basic statistical
ideas to estimate effectiveness and sample size. The mathematical
background of these ideas is introduced in Section 2.
1.3.1. Control strategies for sample size
The question of sample size is typically posed as: how many
subjects are required for testing so that at least, say 85%, of the
existing usability problems are discovered? The usability research-
er aiming for effective usability testing of a medical device, in prin-
ciple has three approaches at her disposal for controlling the
sample size. The magic number approach assumes that all studies
are similar in how fast they reach completeness with increasing
sample size, hence it sets the sample size a priori. Lewis [30] intro-
duced early control where the sample size gets estimated from the
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sources to a project. Unfortunately, it seems that with small sam-
ples, early estimates are far too uncertain to be of practical value
[4]. In consequence, a late control strategy has been suggested that
can guide the process towards the targeted completeness of dis-
covered usability problems [3]. The usability researcher continu-
ously monitors the progress, and invites further participants to
the testing lab, until the preset target is reached with sufﬁcient
conﬁdence. In the current paper, we show how the late control
strategy applies to usability testing of high risk systems, by exam-
ple of a prototype medical infusion pump.1.3.2. Estimating required sample size
All above-mentioned strategies ground on mathematical esti-
mators for the effectiveness of a usability evaluation process, in or-
der to predict the required sample size. Virzi [31] was among the
ﬁrst to propose that the discovery rate d of usability problems fol-
lows a geometric series, depending on the probability of detection
p and sample size n.
d ¼ 1 ð1 pÞn ð1Þ
Reviewing 11 usability evaluation studies, Nielsen and Landa-
uer [32] found that p averages to approximately .31. However, p
seemed to vary considerably between studies (sd = .12), leaving
considerable uncertainty about the effectiveness of a particular
study. Still, many practitioners and academics have come to the
belief that this average p holds for any usability study, hence the
often made recommendation that ﬁve users sufﬁce to ﬁnd 85% of
the problems. Hwang and Salvendy [33] set out to correct the num-
ber 5 by an updated meta study, concluding that the magic number
is to be found in the range of 10 ± 2. In a recent review of this de-
bate, the ﬁrst author reached the conclusion that magic numbers
are simply meaningless [3].
Two mathematical misconceptions led past researchers to over-
rate the average effectiveness of usability testing: assuming homo-
geneity of problem visibility (i.e., a problem’s likelihood of being
discovered) and completeness of problems. Lewis [30] pointed
out the problem of incompleteness with the original geometric ser-
ies model. The naïve estimator for p depends on the true number of
problems as:
p^ ¼ # successful discovery events
# problems sample size ð2Þ
In principle, the true number of problems is unknown to the re-
searcher, since the set of usability problems progressively emerges
with increasing sample size. In the early stages of an evaluation
study, the number of known usability problems can be much lower
than the true number of usability problems. Hence, using the num-
ber of so-far-discovered problems in (1) will grossly overstate p. In
(1), an overstated p yields an overly optimistic estimation of dis-
covery rate d and an underestimation of sample size necessary
for a preset target.
A second insufﬁciency of the geometric series model is that it
assumes homogeneous visibility of all usability problems. That is,
p has the same value for every type of problem [34]. This is an
unrealistic assumption and several researchers have expressed
their disbelief of homogeneous visibility [35,36]. What has long
been overlooked is that variance in visibility of problems substan-
tially decelerates the progress of ﬁnding problems. The 2006 edi-
tion of the International Encyclopedia of Ergonomics and Human
Factors says, ‘‘There is no compelling evidence that a probability den-
sity function would lead to an advantage over a single value for
p.’’[37]. The opposite seems to hold: the assumption homogeneous
visibility is typically false and ignoring visibility variance results inseverely overestimating the true progress in problem discovery
[34].1.3.3. An updated estimator
The now classic geometric series model for sample size estima-
tion is optimistically biased for two reasons: incompleteness is not
regarded and the model assumes homogeneous visibility. Lewis
[30] suggested a ﬁrst solution to incompleteness, a smoothing
method for binomial data known as the Good-Turing adjustment.
Another solution is to use zero-truncated distributions. Zero trun-
cation is the more general solution than the Good-Turing adjust-
ment as it applies to a wider range of count data models,
especially those incorporating visibility variance.
Earlier [4], we introduced the zero-truncated logit-normal bino-
mial model (LNBzt), accounting for both issues: incompleteness
and visibility variance.
With the LNBzt model it is possible to
 estimate the proportion of usability problems that rest
undiscovered at a given point in time,
 extrapolate the evaluation process and predict the required
sample size for a given discovery target, say 85% of the
usability problems,
 determine the accuracy of predictions by constructing con-
ﬁdence intervals.
In Section 2, the mathematical background is explained in more
detail. Furthermore, the appendix of this paper provides the basic
statistical programs necessary to perform the late control strategy
by virtue of the LNBzt model.1.3.4. Representative sampling
The current EU guidelines on usability of medical devices NEN-
EN-IEC 62366 [28] recognizes that diversity of users is an issue (p.
48) and explicitly asks for representative user samples.
As Caulton [35] argued, completeness of problem discovery can
be very much a question of representative sampling. Many factors
may play a role for users’ expectation, interaction style and perfor-
mance in operating a device. Different professional groups may use
a device with different backgrounds, have different tasks and work
under different conditions. Previous experience may have positive
or negative consequences on performance with a newly designed
device [38]. While domain expertise may prevent a user frommak-
ing certain mistakes, experience with legacy devices may cause a
negative transfer [39].
Following the arguments of Caulton [35], discovery of usability
problems likely is incomplete, if a certain subpopulation of users is
omitted. If a user type is omitted or under-represented in the sam-
ple, the usability researcher is at risk to overlook usability prob-
lems that in practice may cause hazards.
The differences between professional groups is explicitly men-
tioned in the FDA draft guidelines [40], pointing out that members
of professional groups potentially differ in their requirements and,
in consequence, experience different problems when working with
a device. The draft guidelines recommend testing 15 users of each
major user group during validation testing.
The current FDA guidelines [22] are less explicit about the sam-
ple size per user group, but make another important point about
user diversity: ‘‘Outlier data from performance measures is often
informative and should be investigated to determine the nature and
pattern of the use scenarios associated with them.’’ (p. 26). Not all
user traits inﬂuencing interaction with the device can be known
in advance, and sampling by professional groups may not capture
the full diversity. Later in this paper, we suggest a procedure to dis-
cover under-represented user groups by identiﬁcation of untypical
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sampling strategy, beyond pure sample size considerations.
1.4. Research question
The aim of this paper is to advance strategies for rigorous
usability testing of medical devices. In the past, much has been said
about effectiveness of usability evaluation methods, see [45] for a
critical review. The focus here is on strategies for managing the
sample. More speciﬁcally, we examine how the LNBzt model ap-
plies to late control of usability testing studies.
First, the overall ﬁt of the LNBzt model will be compared to the
legacy geometric series model. Second, a Monte-Carlo sampling
experiment shows how well the LNBzt model interpolates the ob-
served progress of problem discovery. Third, we examine how con-
sistent sample size predictions are. Fourth, we evaluate reliability
of the discovery process and precision of estimates, by assessing
the amount of uncertainty and volatility in problem discovery.
Fifth, we examine the differences between professional groups
and, ﬁnally, propose a procedure to identify untypical subjects
(‘‘outliers’’) in the sample.
2. Mathematical background
The following sections explain the mathematical background of
the LNBzt model.2 The statistical programs for doing basic sample
size control with the LNBzt model are provided with the electronic
copy of this paper and demonstrated in Appendix A.
2.1. Deriving the geometric series model
The classic geometric series model (1) for sample size predic-
tion can be derived in a number of ways: ﬁrst, it is a growth curve
with diminishing returns. The number of discovered problems
asymptotically reaches the true number of problems (preview
Fig. 3). A consequence of this asymptotic behavior is that with
increasing number of test sessions the gain in terms of newly dis-
covered problems decreases. Second, the geometric series model is
the cumulative distribution function (CDF) of the geometric prob-
ability distribution. The geometric probability function expresses
the probability for a certain number of failures before the ﬁrst suc-
cess in a Bernoulli experiment. In the usability evaluation process
the Bernoulli trials are the participants’ ‘‘attempts’’ to stumble
upon a usability problem.
Finally, the geometric series model can be derived from the bet-
ter known binomial distribution. The binomial probability distri-
bution function pdfBin(k|p,n) expresses the probability of k
successes with n trials and a basic probability of success p.
pdfBinðkjn;pÞ ¼
n
p
 
pkð1 pÞnk ð3Þ
The binomial pdf predicts the number of successes. In usability
testing, however, progress of discovery occurs when a problem has
been observed at least once. The relevant question is: how likely is
it that a problem is discovered at least once, hence k > 0? The
mathematical problem simpliﬁes by taking the opposite event:
how likely is it that a problem remains undiscovered after n ses-
sions, hence k = 0. Let PD(n|p) denote the probability of successful
discovery with basic probability p and sample size n, obtains the
geometric series formula:
PDðnjpÞ ¼ 1 pdfBinðk ¼ 0jn;pÞ ¼ 1 ð1 pÞn ð4Þ2 This section can safely be skipped by the impatient or mathematically inapt
reader.2.2. Overdispersion and a prior for p
The binomial model, from which the geometric series formula
derives, has a remarkable property: variance depends strictly on
the parameter p, as var = np(1  p). If the observed variance ex-
ceeds this term, this is called overdispersion. Overdispersion indi-
cates that probability of success is not ﬁxed for all observations and
instead varies.
When overdispersion occurs, the distribution has fatter left and
right tails compared to the binomial distribution.3 A fatter left tail
means that there is an excess in zero successes, k = 0, problems that
have not been discovered at all. In consequence, when the basic
probability p varies over problems, the binomial model underesti-
mates the number of zero successes, i.e. the unseen problems (pre-
view Fig. 1). It is easily seen from (4), that the geometric series
model overestimates the progress in presence of an excess in zero,
arising from overdispersion.
The issue is solved by adding a prior to the binomial distribu-
tion. The prior is another probability distribution to underlie
parameter p. Priors are commonly used in Bayesian statistics to
model previous belief. Here, the prior reﬂects the random variation
of the parameter in the population of problems. A prior represent-
ing a random effect, not a belief, is often called empirical Bayesian
prior. Statistical models with parameters allowed to vary by a prior
distribution are also referred to as hierarchical models or mixture
models.
The prior for p has to satisfy the range of p, which is the inter-
val [0;1]. A commonly used prior for binomial problems is the
beta distribution [46]. Here, we chose another distribution as
prior, the logit-normal (LN) distribution pdfLN(x|m,s2) [47]. The
LN distribution features a parameter m for the central tendency
and s2 for the variance. It is less common for modeling mixture
models than the beta distribution, but has a few advantages. In
several pilot trials of modeling evaluation process data, the LN
estimation predicted very similar to the beta distribution, but
yielded better precision for the parameters of interest (especially
the number of remaining defects). Another useful model for
researching usability evaluation processes is the Rasch model
from psychometric test theory [48]. The logit is the inverse of
the logistic function in the Rasch model. Under the assumption
that the latent variable is normally distributed, both mathemati-
cal models are fully compatible. Last but not least, interpretation
of the LN parameters m and s2 as average and variance of visibil-
ity is quite natural for a majority of researchers being familiar
with the normal distribution.
Letting p vary according to the LN distribution results in the lo-
git-normal binomial (LNB) probability distribution of the form:
pdfLNBðkjn;m;sÞ¼
n
k
 
1ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
2ps2
p
Z 1
0
pk1ð1pÞnk1e
ðlogitðpÞmÞ2
2s2 dp
ð5Þ
This function does not simplify further, hence solving it requires
quadrature methods for integration. Still, the LNB is a discrete
probability distribution; therefore, deriving the cumulative distri-
bution and quantile (percentile) functions is straightforward. The
cumulative logit-normal geometric distribution function applies
for predicting the rate of discovery. It is derived from the LNB in
the same way the geometric series model was derived from the
binomial distribution in (4).
Given the frequency distribution of how many times usability
problems were encountered, the LNB model allows to estimate
the parameters m (reﬂecting the average visibility) and s23 This is formally expressed by the Two-Crossings Theorem, see [69]. See [4] for an
illustration.
Fig. 1. Fitting the binomial distribution to observed frequency of problem discovery. The ﬁtted distribution does not capture the fat left (and right) tail of the empirical data.
No unseen problems are predicted.
Fig. 2. Fitting the LNBzt distribution to observed frequency of problem discovery. The ﬁtted distribution smoothly captures both tails of the empirical data and predicts 15
unseen problems.
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mum likelihood. By virtue of the added variance parameter, the
LNB model accounts for over-dispersion in the observed frequency
of detection. In particular, it captures the fat left tail of the distri-
bution, resulting in a more plausible estimate for the number of
unseen problems, which is the point k = 0 (preview Fig. 2).4 Throughout, D and d are used as designators for usability problems, as p too easily
confused with probability or the binomial parameter. The reader may imagine ‘‘d’’
s denoting ‘‘defect’’ or ‘‘design ﬂaw’’.2.3. Incompleteness and zero-truncation
The LNB distribution, as introduced so far, has a valid range of
zero to the maximum possible number of discoveries, which is
the sample size n. However, with zero successes as its lower bound,
the model ‘‘expects’’ that the observed data contains the problems
that have not yet been discovered. This is insufﬁcient, because the
researcher does not have any knowledge on the number of undis-
covered problems. And, as will be shown soon, estimating the
number of undiscovered problems, basically is the same as esti-
mating effectiveness. In the following it is outlined, how the model
is adjusted accordingly, which naturally leads to an estimator for
the number of undiscovered problems.
In contrast to the smoothing methods suggested by Lewis [30]
(see Section 1.3.3), here the issue is resolved by limiting the range
of the LNB distribution to exclude k = 0 and re-adjusting theprobability mass to 1. The so called zero-truncated LNBzt function
derives as follows:
LNBztðkjn;m; s2Þ ¼
pdfLNBðkjn;m;s2Þ
1pdfLNBðk¼0jn;m;s2Þ k > 0
0 k ¼ 0
(
ð6Þ
By virtue of the LNBzt probability function, the parameters m
and s2 can be estimated from the observed frequencies of problem
encounters, excluding the undiscovered problems. These estimates
are useful in two ways: First, one can derive a function for progress
of discovery in the same way as the geometric series function is de-
rived from the binomial distribution (see Eq. (4)). Second, one can
easily obtain an estimator for the number of not yet discovered
usability problems4 d0 by entering the obtained estimates for m
and s2 into the non-truncated distribution function. By solving the
equation with k = 0 and multiplying by the number of discovered
problems d, one obtains an estimate d0 for the number of not yet dis-
covered problems:
d0 ¼ pdfLNBðk ¼ 0jn; m^; s^Þd ð7Þis
a
Fig. 3. The Binomial parametric interpolation compared to the chronological progress and a Monte-Carlo sampled interpolation.
Fig. 4. The LNB parametric interpolation compared to the chronological progress and a Monte-Carlo sampled interpolation.
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problems serves as an indicator for incompleteness, or in the oppo-
site, the current level of effectiveness is calculated as 1  d0/d.
3. Method
The following sections describe the procedures and materials
used for usability testing, data gathering and preparation. The sta-
tistical procedures are presented later, together with the results.
3.1. Case study
In our study we tested the computer simulation of a newly de-
signed medical infusion pump, which was developed through an
extensive user-centered process. The study aimed at ﬁnding
usability problems and ﬁxing them during a subsequent redesign
phase.
3.2. Sample
Within two professional ﬁelds, OR anesthesiologists (N = 18)
and ICU nurses (N = 18), were recruited as a convenience sample
(14 males, 22 females). Subjects were employed at the University
Medical Center Utrecht, The Netherlands. Complete and account-
able video data from 34 subjects were available for analysis,excluding two participants due to incomplete video data. Distribu-
tion across age categories was as follows: 20–29 years (n = 13,
38.2%), 30–39 years (n = 10, 29.4%), 40–49 years (n = 7, 20.6%),
and 50–59 years (n = 4, 11.8%). The number of years of infusion
pump experience varied between half a year up to 30 years (with
a total average of almost 12 years; an ICU average of 14.16 years
and an OR average of 9.81 years). In both user groups men were,
on average, more experienced than women. All OR subjects
(NOR = 17) were experienced with the Arsena Alaris infusion pump
and 35.3% of them were also experienced in handling the Braun
infusion pump. For the ICU subjects, all (NICU = 17) were experi-
enced in handling the Braun infusion pump and 5.9% were also
experienced in handling the Arsena Alaris. None of the participants
had used other models, although several have previously worked
in other hospitals. Of the 34 subjects, 28 (82%) replied to the post
questionnaires (13 males, 15 females).
All subjects had normal or corrected to normal vision. All gave
their written consent prior to the test trial and were informed
about the goals of the experiment. No rewards were given for
participation.3.3. Tasks
For this study we formulated a ﬁxed set of 11 tasks covering the
main functions (user goals) of the infusion pump. These tasks were
Table 1
Estimates obtained from the LNB and the binomial model.
D Binomialzt LNBzt
p d0 AIC m s2 d0 AIC
107 0.241 0 1194 1.847 2.256 15 649
5 More than 10 years of professional experience as an inspector for industrial safety
ualify WV as an expert.
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were run through beforehand with three experts (anesthesiolo-
gists) with a view to external validity. These experts did not partic-
ipate in the experiments. All tasks were estimated by the experts to
be of equal difﬁculty and could be carried out independently of
each another to prevent subjects ‘getting stuck’ during the
experiment.
Known (risky) problems in controlling infusion pumps, as de-
scribed in the literature [7,16] were captured in the tasks pre-
sented. Typical tasks were: interpreting the meaning of an alarm,
adjusting values and type of medication, checking pump status
and checking pump history after shift changeover.
3.4. Procedure
The usability testing study was conducted in a hospital setting
in a quiet room with regular artiﬁcial lighting and in the presence
of the facilitator conducting the experiment (WV), who observed
and took notes. At the start of the study, subjects were requested
to complete a consent form and a questionnaire regarding their
demographic details, their experiences in handling infusion pumps
and in using computers in general. Next, subjects were seated in
front of a table on which the apparatus was placed. On the display
of the touch-screen computer, the simulation of the infusion pump
was presented on a blue background. Eleven independent tasks
were programmed into the simulation and task instructions were
presented on paper. Each subject was instructed to perform a com-
plete set of 11 tasks with the use of the touch-screen prototype and
to think aloud concurrently during the performance of the task. No
clues about the tasks were given beforehand or during the task.
Subjects were instructed not to turn to the facilitator for support
or advice during the performance of a task. Before starting the
tasks, subjects were briefed on what the think-aloud protocol en-
tailed. With their consent, video and audio data were gathered dur-
ing the experiment to capture task slips and mistakes made by
subjects. Screen captures were also recorded. After completing
each task, subjects had to independently reﬂect aloud on their pre-
vious task performance, without guidance of the facilitator. One
minute was available for providing retrospective feedback after
which the next task was loaded for completion. All eleven tasks
were presented and evaluated this way. After completion of the
whole test (i.e., all 11 tasks), subjects were asked to complete three
post questionnaires, concerning (1) their experiences with having
to think aloud, (2) the appearance of the prototype and (3) han-
dling the pump during task performance. The third questionnaire
was structured according to cognitive and ergonomic design prin-
ciples. For planning, designing and conducting this usability testing
study and for related questionnaires, we used Rubin’s handbook
[49]. In conducting the usability test, ﬁrst the anesthesiologist user
group was exposed to the simulation, followed by the ICU user
group.
3.5. Data preparation
Video-taped observational data and audio-recorded interviews
were examined for critical incidences – observations and retro-
spective comments. These were aggregated to 123 usability prob-
lem descriptions using the method of similar changes [50].
Problem sets from usability evaluations reportedly contain false
positives; experts or users may comment on design aspects that in
fact do not harm usability [51]. Consequently, a subsequent review
was undertaken to sort out false positives.
The 123 potential usability problems were reviewed in a three-
step triage-like procedure to separate usability problems from
irrelevant observations: First, problems that were directly ob-
served during interaction were always taken as valid problems.Second, the remaining problems were individually mapped to the
matching questions of the post-test questionnaire. Problems that
were related to at least one negative rating were taken as valid.
Problems related to unambiguously positive satisfaction ratings
were taken as potential false positives and ﬁnally underwent an
expert screening (WV).5 By this procedure, 16 problems were dis-
carded as almost sure false positives and NP = 107 problems re-
mained in the data set. Note that the following data analysis is
strongly based on frequency of problem occurrence. In the triage,
problem frequency was not taken as a criterion for problem validity,
in order to prevent circular conclusions.3.6. Developed software
We created a collection of statistical routines within the scien-
tiﬁc computing environments R [52] and provide it in Appendix A.
The collection contains the standard probability functions to work
with the LNBzt. A number of high level functions are provided to
perform the late control strategy. Appendix A is a tutorial on instal-
lation and demonstration of use of the programs.4. Results
We present the results from four perspectives: First, the state of
affairs after the study has completed with n = 34 is analyzed a pos-
teriori. The LNBzt model’s ﬁt is assessed and compared to the legacy
geometric series model. Then follows a chronological analysis,
describing how the study progressed, and showing how the LNBzt
supports the late control strategy. Third, the as-if analysis com-
pares the chronological process to alternative sequences of partic-
ipants. During the chronological and as-if analyses, unexpected
jumps in the progress are observed. The ﬁnal analysis looks at atyp-
ical detection patterns of participants as a possible cause and intro-
duces the idiosyncrasy score.
The data set contains n = 34 independent sessions. After the tri-
age a set of 107 conﬁrmed usability problems remained, for
example:
 Parameter ‘weight patient’ is most often ﬁlled in at ﬁrst, but
presented at the bottom of the list in the supporting calcu-
lation function.
 Meaning of button BOLUS not clear. Often misinterpreted
as a mark.
 OK button has different meaning in selecting parameters,
afﬁrming and navigating. Several subjects were unsure
about the consequences of pressing OK in several
situations.
 Absence of feedback after activating the bolus.
 Absence of the option to ﬁrst turn off the alarm sound and
then take action (an ICU has to be as quiet as possible).
 A green light is on, even when the pump is not running,
although this can be an undesired or harmful state.
Participants discovered a problem 877 times. According to (2),
the naïve discovery rate is 24.1%. The least sensitive participantq
8 Three sessions is the smallest possible sample size for obtaining LNB estimates.
9 Often researchers resort to asymptotic normality of the likelihood function and
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a mean of 25.79 discoveries per participant (24%). 14 participants
contributed at least one problem they discovered exclusively.
Problems ranged from 1 to 28 in how often they were recorded.
19 problems were discovered by at least half of the participants. 18
problems (17%) are singletons; they were recorded on one partici-
pant only.
4.1. Posterior analysis and extrapolation
Both, the binomial and LNB model are estimated via the maxi-
mum likelihood method using the margin sum on problems (i.e.,
the frequency of discovery). Figs. 1 and 2 show the observed mar-
gin sums compared to the estimated models. Apparently, the ob-
served distribution has a much fatter left tail and a longer right
tail than the binomial model. The observed variance of 49.3 ex-
ceeds the variance expected under the binomial model of
107  0.24  (1–0.24) = 19.5. This excess in variance is an indica-
tion for overdispersion; problems vary in visibility.
Table 1 shows the results of the two competing models: The
zero-truncated binomial model predicts that the study is complete
– no problems remain undiscovered (d0 = 0). The LNBzt model, in
contrast, predicts that d0 = 15 problems remain undiscovered,
which equals a discovery rate of only 88%. The lower Akaike Infor-
mation Criterion (AIC) of the LNBzt model conﬁrms the much better
ﬁt, even though this model is more complex (i.e., less parsimoni-
ous).6 The parameter s2 is clearly positive, indicating strong variance
in problem visibility.
The following analysis interpolates the progress of ﬁnding prob-
lems. A parametric interpolation of the progress is created using
the estimates from Table 1, comparing the geometric and logit-
normal geometric series models. Figs. 3 and 4 show the match be-
tween interpolation by the two models and the observed progress
of the study. The observed progress is represented in two different
ways: First, the chronological progress of ﬁnding problems as it
happened during the study is plotted. Second, a Monte-Carlo
(MC) sampled progress with 500 random realizations of every pos-
sible sample size between 1 and 347 was created. A problem for the
MC interpolation arises from the potential incompleteness. As we
have seen, the LNBzt estimation indicates around 15 (12%) not-yet
observed problems. Based on the 107 observed problems alone,
the chronological progress and the MC interpolation both will neces-
sarily arrive at 100%, whereas the parametric interpolation arrives at
88%. We solved this pragmatically by imputing d0 = 15 virtual prob-
lems (i.e., the most likely number of unseen problems). This proce-
dure may appear somewhat tautological. However, it merely ﬁxes
the position of the end point at n = 34. The overall curvature of the
progress function is not affected; deviations may well occur, show-
ing that the interpolation does not ﬁt well.
No such imputation was necessary for the binomial/geometric
model, as it predicts zero unobserved problems. Fig. 3 shows that
the chronological and MC progress are very close, with some wav-
iness of the chronological progress. In contrast, the geometric series
interpolation shows a curvature very different from the observed
progress. At any given moment, the parametric interpolation over-
states the progress. For example, according to the geometric series
interpolation the 85% target was met with eight sessions already. In
fact, only 85% of the known problems were discovered after session
13. This calculation does not even consider possibly undiscovered
problems (as indicated by the LNBzt model).
In contrast, Fig. 4 reveals a good match between the LNBzt para-
metric interpolation and the observed progress (MC and chrono-6 For an introduction to model selection with information criteria see [70].
7 Note that there are only 34 different realizations at n = 33 and only one at n = 34
derive conﬁdence intervals from the Fisher information function. In contrast
bootstrapping is a resampling method, which has better accuracy at small sample
sizes und with exotic models. While bootstrapping is easy to implement, it is
computing intensive. The intervals here were computed by 500 bootstrap samples in
steps of four sessions..logical). Whereas the MC interpolation closely resembles the para-
metric interpolation, the chronological progress shows a few devi-
ations. The strongest deviation is observed for the ﬁrst participant,
ﬁnding 39 (32%), instead of the expected 25 (21%) problems. Also,
participants 3, 12 and 22 show an above average yield in new prob-
lems. Note that due to the cumulative nature of the process, an
above average contribution declines only gradually with further
session. For example, at session 5 the observed progress is still
above expectation, but we cannot attribute this to an extraordinary
contribution of participant 5. In a later section, we will scrutinize
further the volatility of the process due to individual contributions
of participants.
The poor ﬁt of the binomial marginal sum (Fig. 1), the lower AIC
and unrealistic estimate for d0 (Table 1) and the strongly deviating
interpolation (Fig. 3), add to the growing body of evidence that the
geometric series formula is inappropriate for predicting the usabil-
ity evaluation progress [3,4,34,53]. Consequently, the following
sections will pursue analysis with the LNBzt model only.
Finally, the 88% discovery rate obtained with 34 participants is
sufﬁcient information to initiate another iteration in the develop-
ment cycle. If this were a ﬁnal validation study, 88% appears rather
low. With the LNBzt estimates we can extrapolate the process of
discovery: the 90% discovery target (109 problems) is met with
n = 42, while the 95% discovery target (115 problems) is met with
n = 79. A 99% rate will require testing 255 participants.
4.2. Chronological analysis
The previous section has shown a good ﬁt of the LNBzt, raising
expectations that researchers can use the model for monitoring
and prediction of the usability testing study. The following analysis
reverts to the chronological order of events in the study, and intro-
duces conﬁdence intervals for making decisions under uncertainty.
For demonstrating the late control strategy, it is assumed that the
researcher is aiming at a target of 85% problems discovered. After
testing every new subject, the researcher estimates the proportion
of discovered problems d0. Employing the full data set, the 85% tar-
get seems to be reached at about 28 or 29 sessions.
Starting now with session 3, the discovery rate is estimated as
the number of discovered problems divided by estimated total
number of problems at every new session.8 As shown in Fig. 5,
the point estimator for completeness deviates strongly from the true
and interpolated progress at small sample sizes. Relying solely on
the point estimate, the researcher is at risk to stop the study prema-
turely after session 8, where 76 problems were discovered and the
number d0 = 11 undiscovered problems are estimated. Hence, the
estimated total number of problems is grossly understated at that
point (as compared to the posterior estimation). With session 12,
estimated completeness again drops below 85% and starts converg-
ing to chronological progress and parametric interpolation, with
some ongoing optimistic bias.
Apparently, point estimates are not very precise. As expected by
the law of large numbers, the strongest deviations happen at small
sample sizes. For decision making under uncertainty, conﬁdence
intervals are recommended practice. In the next step of our analy-
sis, conﬁdence intervals are constructed via the bootstrapping
method.9 Fig. 5 shows three ranges (50%, 80% and 95% conﬁdence).
Even the most liberal 25% limit effectively guards against prema-,
Fig. 5. Estimated completeness in chronological order compared to the chronological process. Dotted lines are conﬁdence limits obtained by bootstrapping in steps of four
sessions.
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moderate sample sizes, the chronological progress crosses both inner
lower conﬁdence limits (25% and 10%). Even the 2.5% limit would not
prevent premature termination under all circumstances. Setting a
lower target, say 55% would have resulted in a mistaken termination
at n = 7. However, one can hardly think of a scenario where the re-
searcher wants to apply quantitative sample size management and
at the same time have such a low target.4.3. As-if analysis
The previous section has shown that the LNBzt model is consis-
tent with the empirical progress a posteriori, when estimates are
obtained with the maximum data available at n = 34. However,
there were serious deviations observed when tracing the chrono-
logical decision process. Unfavorably, the deviations were mostly
optimistic, leaving a risk of stopping the study too early. It is un-
clear whether this happened due to a systematic bias of the LNBzt
model or due to randomness in the process. Next, we examine both
possibilities with two Monte-Carlo studies. The ﬁrst MC study
examines whether the LNBzt estimates depend on sample size, pos-
sibly under-estimating at smaller samples. The second study
examines the volatility of the stochastic process, by sampling
100 alternative sequences from the data.
If the LNBzt estimator is unbiased at small sample sizes, it can be
expected to give the same estimation for the total number of prob-
lems and the required sample size at different sample sizes, on
average. In a Monte-Carlo experiment, 500 participant groups of
sizes 10, 15, 20, 25 and 30 are randomly picked from the full data
set. For every subsample, estimates for m and s2, the total number
of problems and the required sample size for a 90% target10 are
obtained.
As can be seen in Fig. 6, the average predicted sample size is not
fully independent of the mean, but steadily increases from 32 to
40. The same small-sample bias happens with the estimated num-
ber of problems (Fig. 7). Again, there is strong uncertainty at small
to moderate sample sizes, which diminishes steadily, but is still
signiﬁcant at n = 30.
The chronological estimations in Fig. 5 deviated signiﬁcantly
from the chronological progress, in an optimistic direction, typi-
cally. It seems obvious to attribute this to the sample size bias, just10 The reason to choose 90% this time is that this target is not met in the study,
hence it is a real prediction.observed. However, this bias is rather small and would not explain
the roughness of the estimated completeness curve. As we have
outlined in the beginning (and will scrutinize further in the follow-
ing section), subjects differed in how many observations they
contributed. Hence, the order of subjects may cause deviations
from the ideal progress curve. Another MC analysis may give an
idea of the inﬂuence of the sequence at which subjects are tested.
One hundred random sequences from the data set were generated
for the following descriptions. Fig. 8 serves as an illustration with
the number of random sequences limited to 25 for better legibility.
The ‘‘caterpillar’’ plot below the curves indicates which proportion
of alternative sequences have a lower or higher performance com-
pared to the chronological. The chronological (i.e., true) sequence
outperforms most other sequences between sessions 1 and 5, then
gradually drops below the median at sessions 8–10, with poorest
performance at session 9. Between session 12 and 17, the chrono-
logical sequence takes another over-performing turn, then brieﬂy
moves back to average, followed by another high performing
episode.
It appears that the evaluation progress signiﬁcantly depends on
the sequence at which participants arrive in the lab. The chrono-
logical sequence in our study, on average is among the better per-
forming ones. The strongly over-estimated completeness at small
sample size, as observed in Fig. 8, can be attributed to the fact that
the ﬁrst few sessions were truly far above expectations, for what-
ever reasons. In conclusion, the small sample bias is hardly deni-
able; but does not stand out against the level of randomness and
volatility observed.
4.4. User groups
The European [28] as well as US [22,40]. Human Factors guide-
lines for medical devices emphasize representative user sampling
for effective validation testing. The common assumption is that dif-
ferent professional groups have their own requirements and in
consequence experience different usability problems.
The sunﬂower plot in Fig. 9 shows the discovery frequency of
usability problems depending on the professional group. The cloud
of points appears fairly coherent and mostly resembles the diago-
nal; the differences between the two groups may not be very pro-
nounced. One can spot a leaning towards the OR axis, indicating a
higher sensibility of anesthesiologists. Still, a number of problems
were exclusively discovered by either anesthesiologists (20, 19%)
or nurses (12, 11%). But, the most of these problems have a very
low overall discovery rate.
Fig. 7. Estimated total number of usability problems by sample size.
Fig. 8. Alternative sequences of the evaluation process compared to the chronological order. Inline chart shows the proportion of sequences outperforming chronological
sequence (above the line) and outperformend by it (below the line).
Fig. 6. Predicted required sample size for a 90% discovery target by sample size.
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effectiveness of mixed group samples to ‘‘pure’’ samples [54]. If
the two groups differ in their sensitivity for individual problems
(not to be confused with the average effectiveness), then mixedgroups must have an advantage in effectiveness due to a comple-
mentarity effect [55]. In a Monte-Carlo experiment, 500 samples
of n = 10 users were created in three conditions: pure OR groups,
pure IC groups and half-half mixed groups. Fig. 10 shows the
Fig. 9. Frequency of discovery of usability problems by professional group.
IC = Intensive care nurses, OR = Anesthesiologists. The number of ‘‘petals’’ indicates
the number of problems at each point.
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the three sampling conditions. Pure OR groups have an overall
higher effectiveness (m = 82.8, sd = 2.93) compared to pure IC
groups (m = 77.65, sd = 2.91). The mixed groups have quite the
same mean effectiveness as the OR group (m = 82.66, sd = 4.2). If
both professional groups differ in overall sensitivity only, without
any qualitative differences, we would expect the mean effective-
ness of the mixed groups somewhere between the pure groups.
As this is not the case, the disadvantage of the IC group’s overall
lower sensitivity is compensated for – qualitative differences be-
tween the two professional groups exist.
4.5. Idiosyncrasy
In Section 4.3, it was observed that the progress strongly de-
pends on the order of subjects entering the study. Predictors from
sessions grossly deviated from the interpolation. Fig. 5 already pro-
vided some indications as to the reasons why: Subject 1 has an ex-
treme sensitivity without doubt, discovering about one third of all
problems. What is surprising at ﬁrst glance is that progress and
estimated completeness often seem to take opposite directions.
This is particularly the case at session 8: not a single new problem
is discovered, in consequence chronological completeness drops
below expectation and at the same time, estimated completeness
peaks.
In fact, this observation is well in line with the mathematical
relation between the distribution of margin sum and the progress
curve: When a subject discovers many new problems, thisFig. 10. Distribution of effectiveness (number of discovered problincreases the left tail of the frequency distribution (review
Fig. 2). This has two effects: variance increases and average discov-
ery rate decreases. Increasing variance and decreasing mean both
result in higher estimates for d0, indicating a lower completeness.
The exact opposite happens, if a subject only rediscovers problems
(such as subject 8): the left tail gets thinner and the distribution is
shifted to the right; higher estimates for completeness are
obtained.
A chronological plot, as in Fig. 5, is not optimal to judge individ-
ual predispositions for several reasons: First, the extreme effects of
one untypical subject decays only gradually when further subjects
are added. In turn, the effect a subject depends on the history. Sec-
ond, at small sample sizes the process is highly volatile; even
rather typical subjects may show extreme peaks. Third, the process
stabilizes with increasing sample size; even highly untypical sub-
jects no longer stand out. And ﬁnally, the curvature makes visual
examination cumbersome.
Based on the above considerations, atypical subjects may be
identiﬁed by measuring individual subjects’ relative contribution
to the estimated total number of problems ND (or d0, likewise).
Subjects being very representative for the overall sample, pull
the estimate down, subjects with rather uncommon discovery pat-
terns push it up.
For determining the relative contribution of individual subjects
to the estimate ND, we devise a jackknife estimator. Jackknife esti-
mation is a resampling method, where one omits one observation
in every run. In the case of usability testing data, an idiosyncrasy
score is constructed for subject i as the ratio between ND estimated
from the full sample and ND(i) estimated by omitting subject i.
When the idiosyncrasy score ND/ND(i) > 1, subject i by tendency
contributed rarely discovered problems and can be called atypical.
The researcher may then investigate deeper to ﬁnd out what makes
this subject special, for instance by looking at demographic data, a
post test interview, or looking for a common theme in the prob-
lems recorded on subject i.
A second property of interest is a subjects’ overall sensitivity to
usability problems. A scale for sensitivity is straight forwardly con-
structed as the individual discovery rate divided by the average
discovery rate (24.1%).
Fig. 11 displays all subjects on a plane spanned by sensitivity
and idiosyncrasy. A linear regression with idiosyncrasy as predictor
for sensitivity conﬁrms near independence (F(1,32) = 1.11,
p = 0.30,g2 = 0.03). Apparently, the two properties are well separa-
ble in the detection patterns.
Subject 1 turns out to be extremely sensitive, at the same time
being rather representative. That means, chances are good that di-
rect followers of subject 1 have a higher rate of re-discoveries. High
rates of re-discoveries are an indicator for approaching complete-
ness. This explains the strong over-statement of estimated com-
pleteness in the early process. As can be seen from Fig. 5,
estimated completeness takes a sharp rise with subject 5, being
highly sensitive as well. Subject 7 has a similar proﬁle, slightly less
idiosyncratic and sensitive and the corresponding rise in estimatedems) in pure and mixed groups by 500 Monte-Carlo samples.
Fig. 11. Subjects by idiosyncrasy and sensitivity.
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osyncrasy of all, which is impossible to spot in Fig. 5 because the
process has mostly stabilized. In turn, most subjects in the range
8–13 are rather representative (i.e. they tend to rediscover prob-
lems), explaining the steadily climbing completeness.
Subjects 5 and 7 (both OR) and 28 (ICU) reveal the strongest idi-
osyncrasy. Based on the limited demographic data available in this
post hoc analysis, none of these subjects had one or a combination
of eye-catching properties.
5. Discussion
Our results showcase the LNBzt model for quantitative control
of usability testing high risk systems. The LNBzt model provides
estimates of much better consistency than the legacy geometric
series model. It may therefore serve the late control strategy for
sample size. Volatility and uncertainty of the evaluation process
are strong. In evaluation of high risk systems this calls for large
sample sizes, far beyond past recommendations. Furthermore, we
analyzed our data with respect to the composition of samples. Dif-
ferences between users exist, and must be taken into account for
effective problem discovery.
5.1. Required sample size
The required sample size in this study is much larger than pre-
dicted by the prevalent binomial/geometric model and the magic
numbers [26]. Common arguments why Nielsen’s claim of ‘‘85%
with ﬁve users’’ may not hold, are: the complexity of modern prod-
ucts [24] and the diversity of users [35]. This insufﬁciently explains
our ﬁndings, because we tested a fairly simple device (compare the
few controls and parameters to, let’s say, an ofﬁce productivity
suite), with a rather homogeneous sample of professional users.
In conclusion, we ﬁnd our previous results conﬁrmed that pro-
posed magic numbers are far too small [3,4].
Medical devices are embedded systems for professional use; as
such they have lower innovation rates than consumer products.
Furthermore, developing devices for safety–critical tasks in dis-
tracting work environments justiﬁes rigorous testing. As of writing
this, the FDA is working on a standard for user-centered develop-ment of medical devices [40]. The FDA Draft Guidance also ad-
dresses the issue of sample size, but is cautious with deﬁnitive
recommendations. Fortunately, it does not resort to any magic
numbers, but instead illustrates the increase in effectiveness and
stability by a ﬁgure taken from [56]. However, it has happened be-
fore that a statement like ‘‘on average the probability of discovery
is p = .31 and this means ﬁnding 85% of the problems with 5 users’’
degenerates over time to ‘‘Five users will ﬁnd 85% and this is en-
ough.’’ Proponents of ‘‘discount usability’’ prolong the ‘‘Five users
is enough’’ claim [57], without seriously referring to the growing
body of counter-evidence and mathematical considerations.
In our study, a reasonable discovery rate started at a sample size
of 25–30. This was not intended as a validation study, but to initi-
ate another iteration of design. Validation studies may call for
much larger sample sizes, maybe in the magnitude of pharmaceu-
tical clinical trials.5.2. Uncertainty and precision
Faulkner [56] examined the effect of sample size on effective-
ness; her primary conclusion was that increasing sample size
makes the process more reliable. Our results conﬁrm that effective-
ness of usability testing is highly uncertain with small to moderate
sample sizes. Accordingly, estimators for completeness are highly
volatile.
Hence, large sample sizes are required to get stable results and
precise estimations of completeness, if this is desired. We strongly
recommend that researchers always compute conﬁdence limits
when making decisions in the fashion of late control. In our study,
LNBzt estimates were more credible than the binomial model, but
still are at best asymptotically consistent. In small samples, re-
quired sample size and number of problems are slightly underesti-
mated. With moderate to large samples sizes, estimates seem to
converge with the truth.5.3. Frequency and loss, false alarms and black swans
Sauro [58] argues that rarely and late occurring problems are
less severe, because they only affect a small fraction of users. In
our study we did not rate severity of problems. What comes closest
to a severity judgment is the three-level triage to sort out the false
alarms. Indeed, problems classiﬁed as false alarms appeared to oc-
cur at lower frequencies. Virzi [31] reported that highly critical
usability problems are found quickly. In contrast, Lewis could not
replicate this relationship [59]. So, it may or may not turn out that
critical problems are observed at a quick pace and sample size
requirements can be relaxed. However, Virzi tested a voice com-
mand system with severity judged by six experts, whereas Sauro
refers to an e-commerce system. Expert judgments may carry
biases and blind spots; and for medical infusion pumps, what is
critical can mean something very different compared to a 90s voice
command system or a webshop.
Most studies on effectiveness of user testing have web sites,
business systems or consumer products as object of evaluation;
not embedded medical systems, where the loss due to an unde-
sired event can have extremely adverse consequences for patients.
Use errors due to unﬁxed usability problems my turn out ‘‘black
swans’’, low frequency events with an extremely high loss [60].
In consequence, any procedure of limiting or discarding obser-
vations, has to involve either a complete risk analysis, or at least
be very conservative, like the triage in our study. Stop rules for
sample size must give rare events enough headroom. In fact, it fol-
lows from our mathematical considerations that the decline of
once-discovered problems is a better indicator for approaching
completeness than the average discovery rate.
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to predict unfavorable outcomes of millions of daily events, in a
variety of complex and dynamic situations and involving diverse
users, by a few dozens of video tapes, recorded under more or less
controlled lab conditions.
5.4. Managing user diversity
The two professional groups, anesthesiologists and nurses, dif-
fered in discovery of problems. Anesthesiologists were more effec-
tive, and exhibited a partially different set of problems. These
differences are moderate. In an earlier publication, the ﬁrst author
applied the same Monte-Carlo approach to compare evaluation
methods and found much stronger differences [55]. Furthermore,
the difference in average effectiveness found in our study is not a
general fact. Sampling strategies must not be based on false gener-
alizations, like higher educated users being more effective at prob-
lem discovery. Diverse user samples make problem discovery more
efﬁcient by the mutual compensation of ‘‘blind spots’’.
Individuals differed in their disposition to discover usability
problems, in quantity and quality. Some subjects are generally
more sensitive to usability problems, others seem to have more
or less different problems when operating the device. Like problem
visibility, variance in subject’s sensitivity seems to be the norm
[34]. However, as argued there, sensitivity variance does not have
the same unfavorable impact as visibility variance. Quite the oppo-
site, highly sensitive subjects make an above average contribution
to the incremental progress of problem discovery.
One can also view the progress of discovery as a saturation pro-
cess. Imagine, a usability researcher has identiﬁed two potential
user groups A and B, and has invited representatives of A and B
to the usability lab. After testing 35 participants, the discovered
number of problems starts to converge with the estimated number
of problems. Then, it is futile to test further participants of these
groups. But, the researcher may have missed a user group C, having
different expectations on how to interact with an infusion pump.
Fortunately, a few members of group C were in the sample. Their
number is not sufﬁcient to discover most of their speciﬁc problems,
but maybe they can be identiﬁed by untypical patterns of
discovery.
For this particular purpose we suggest the idiosyncrasy score.
Usability researchers should beware of seeing idiosyncrasy as
unfavorable, in the fashion of social science researchers removing
outliers in their samples. Untypical subjects report on less frequent
problems, pushing the discovery process forward. As a disclaimer,
the idiosyncrasy score cannot identify what is completely outside
the study. Researchers must take care of the composition of their
samples.
5.5. Limitations of the study
The results and conclusions reported were based on observa-
tions in a single case study, generally limiting the level of general-
izability. In particular, all estimates reported here are limited to the
system and the sample studied. Mean and variance of problem vis-
ibility, as well as required samples size vary widely between stud-
ies [4,32,34], and one must not derive any general rule, such as
‘‘85% of problems are found with 13 participants’’ (Section 4.1).
The same caution is in order for any other ﬁndings, such as the le-
vel of uncertainty (Section 4.2), volatility (Section 4.3) and differ-
ences between professional groups (Section 4.4). However, the
general ﬁnding, that ignoring visibility variance leads to an under-
estimation of the required sample size, matches previous results
[3,4,34].
While it is our main stance that rigorous testing of medical de-
vices requires larger sample sizes than is suggested in most of theusability literature, we have deliberately chosen not to argue
against another principle of discount usability engineering, itera-
tive testing. In particular, iterative testing has two merits: ﬁrst,
redesigning an interface may remove usability problems, but
may also introduce new ones [61], which is only discovered by
re-testing the updated design. Second, major usability problems
may distract from or even obscure other problems. These may be-
come visible only after removing the ‘‘catastrophe’’ in another re-
design cycle (see also the following section).
In most analyses performed, we resorted to a target of 85%, but
did not evaluate the performance of the model at more liberal or
strict targets. To some extent, choosing the 85% target is too lenient
as we are aiming at rigorous testing in high risk environments. The
reason for our choice is to make comparison easy, since many past
papers refer to this ‘‘magical’’ target. Also, we could not reach a
much higher target with our comparably large sample size.
The severity of usability problems was not directly assessed. It
may turn out that severe problems tend towards being discovered
early, justifying smaller sample sizes. This has been discussed in
Section 5.3.
Subject 1 was outstanding with unmatched sensitivity and
strong representativeness. One may suspect that this is an order ef-
fect as subject 1 also was the ﬁrst session analyzed. Possibly, the
classiﬁcation scheme for usability problems was inﬂuenced by
the early observations, as kind of an anchoring effect. Indeed, sev-
eral studies show that analyzing data from usability testing studies
is a highly subjective process [62–64]. Further effort is needed to
standardize the whole process of qualitative data analysis of
usability testing medical devices.
5.6. Limitations of the approach
The presented approach for estimating the required sample size
acknowledges variance in visibility of problems, but does not ac-
count for variability of the population of users. As we have argued
above (5.4), this issue is in fact two-part: users can differ in overall
sensitivity or sub-groups of users can exist, that differ qualitatively,
experiencing different set of problems.
By virtue of the LNBzt model it is well possible to estimate var-
iance in sensitivity, as has been demonstrated earlier [34]. The rea-
son to not include a parameter for sensitivity variance is that, in
fact, it has little impact on the estimation of undiscovered prob-
lems. Compared to the strong liberal bias when omitting variance
in visibility (the main stance in Section 4.1), variance in sensitivity
adds a very small bias, that is conservative. Rivest proved this
mathematically [65], and we veriﬁed Rivest’s conclusion in inter-
nal simulations. So, adding another parameter for sensitivity vari-
ance is possible, but complicates matters without signiﬁcant
practical value.
It is likely, that in a situation where distinct user groups expe-
rience different sets of problems, larger sample sizes are required.
We presume that, as long as all subgroups are adequately repre-
sented, the LNBzt accounts for this sort of heterogeneity. If a sub-
set of problems is speciﬁc for a subgroup of, let’s say, one third of
the participants, this would simply mean that a certain number of
problems has a lower overall visibility, which is readily accounted
for by the LNBzt model. Ultimately, compiling a representative
sample is at the discretion of the researcher. In principle, no
mathematical model can correct for omissions of relevant user
groups. By introducing the idiosyncrasy score we believe to have
contributed to the identiﬁcation of under-represented user
groups.
However, the idiosyncrasy score has been suggested here, but
not fully validated. While we identiﬁed a few ‘‘outlying’’ subjects,
the available demographic data could not explain high
idiosyncrasy of some subjects. Note however, that the very idea
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tween highly idiosyncratic subjects. Further research is required to
validate and perhaps adjust the idiosyncrasy score.
Besides user heterogeneity, there are other factors that impact
identiﬁcation effectiveness, but are not directly accounted for by
the LNBzt estimation. Most notably, Lindgaard and Chattratichart
found that task coverage had a strong impact on effectiveness of
problem identiﬁcation [66]. Like with sampling users, preparing a
valid, representative and well-formulated set of tasks is at the dis-
cretion of the researcher, as it can hardly be accounted for mathe-
matically. However, the LNBzt approach potentially lends itself to
also steer the administration of tasks. By estimating on the subset
of problems that have been identiﬁed within a particular task, one
can track the exhaustion of individual tasks. When the number of
undiscovered problems approaches zero, an exhausted task can be
replaced, ultimately maximizing the information gain. Researchers
can readily try this strategy with the provided programs.
The obscuring effect of major problems (‘‘catastrophes’’, see Sec-
tion 5.5) likely exists, but is not directly accounted for in the LNBzt
model. Too little is currently known about this effect to attempt
proper mathematical modeling. Statistical models for association
rules (e.g., for market basket analysis) may be applicable, but re-
quire impractically large data sets [67]. Furthermore, the obscuring
effect not necessarily imposes a strong bias on the LNBzt prediction.
For illustration, assume two problems A and B, that have about the
same visibility. However, A often (but not always) leads to a catas-
trophe, obscuring B, thereby reducing its factual visibility. In such a
case the LNBzt model would ‘‘detect’’ a lower mean visibility and
stronger visibility variance, and ultimately predict a large number
of undiscovered problems. So, the mere fact that some problems
are discovered at a low rate, lets the model ‘‘assume’’ that there
must be more undiscovered problems, which is plausible. Further-
more, detecting the obscuring effect does not require a statistical
model: if a participants are repeatedly unable to complete a task
due to a major problem, the researcher is advised to stop the study
and initiate another redesign cycle.
While the LNBzt, may sufﬁciently account for a number of pecu-
liarities that are not explicitly modeled, there is one principal limi-
tation: The model is parametric and, in particular, makes the
assumption that problem visibility is normally distributed. This is
an approximation, and as such, prone to violation by real data, lead-
ing to biased predictions. For example, Cahoy and Phoha [68] pro-
pose Bernstein polynomials as an alternative to model the
probability density. Further studies are needed to explore potential
biases that arise from the mathematical assumptions, using real
and simulated data. It is our hope that the provided programs stim-
ulate critical evaluation of the LNBzt model in particular, and the
practices of testing high risk systems in general.
6. Recommendations
Developers of interactive medical devices are at risk to overlook
usability problems, and in consequence end up with design ﬂaws,
potentially causing hazards. For effective usability testing in high
risk domains, we recommend:
 Plan for large sample sizes, far beyond what ‘‘discount
usability’’ practices suggest.
 Apply the late control strategy: Continuously monitor pro-
gress of the study using preset targets and predictive
models.
 Use predictive models that account for visibility variance
and unseen events. Ignore legacy approaches like the geo-
metric series model and magic numbers.
 Calculate conﬁdence intervals to account for uncertainty,
especially at small to moderate sample sizes. Use representative samples of users, include all profes-
sional groups and think of other user traits in advance.
 Monitor the results for untypical users. Never discard out-
liers, but take them as guides to adjust the composition of
the sample.Appendix A. Installation and use of statistical programs
A.1. Installing R
1. Go to www.r-project.org and download a recent copy of R for
your operation system.
2. Run the setup program and follow the instructions.
When working with R more frequently, it is recommended to
use an integrated development environment, such as Rstudio
(www.rstudio.org).
A.2. Preparation
3. Create a directory hdiri for the library and data to reside in.
4. A library, a program and a data ﬁle are provided with the elec-
tronic version of this paper. Download all ﬁles to hdiri.
5. Open the ﬁle tutorial.R with an R editor.
6. In the ﬁrst line, change setwd(. . .) to reﬂect the working direc-
tory hdiri (Windows users are reminded to use ‘‘/’’, instead of ‘‘/’’
for directory paths). The statistical routines are collected in the
ﬁle ‘‘LNBPrediction.R’’. They are read in by the subsequent
source(. . .)command.
7. R is an interactive programming language; it is recommended
to walk through the tutorial by issuing the command one by
one.
A.3. Loading data
The basic data format used is the binary detection matrix, with
problems in rows and subjects in columns. Cell i, j in the detection
matrix is set to 1, if problem j was discovered by subject i, other-
wise 0. Boolean values may be used instead.
Most easily, a detection matrix is prepared in a spreadsheet pro-
gram, such as Microsoft Excel. As R cannot read the native format
of spreadsheet programs, one has to save the detection matrix as a
CSV ﬁle. The following command reads a plain detection matrix
(without any row or column names) in CSV format, and creates a
data frame variable DM:
DM <- read.csv(‘ detectionmatrix.csv’ )
Later, the data can be saved in native R format by issuing:
save(DM, file=’’detectionmatrix.Rdata’’)
and reloaded by
load(file=’’detectionmatrix.Rdata’’)
The example ﬁle ‘‘infpump.Rdata’’ provided with the electronic
version of this paper is a partial detection matrix of the infusion
pump study, with 20 randomly chosen subjects. It is used in fol-
lowing walkthrough.
A.4. Estimating completeness
The central high-level function provided is ﬁt.LNB, which ﬁts the
LNBzt distribution to the data, more speciﬁcally, the margin sum on
problems. The margin sum is easily obtained by issuing ﬁrst:
640 M. Schmettow et al. / Journal of Biomedical Informatics 46 (2013) 626–641MS <- rowSums(DM)
Then, the ﬁtting results are stored to a variable ﬁt by:
fit <- fit.LNB(MS, 20)
If all goes well, the estimated completeness can be obtained by
D.hat(fit)
The number of undiscovered problems is obtained by:
D.null(fit)
Remember, that ﬁtting the LNB strongly bases on numerical
integration and optimization, which can fail if the data is sparse,
or parameter values are extreme. In case the program throws er-
rors, changing the starting values for the maximum likelihood esti-
mation typically helps. For example the following statement sets
the starting value for m to 2 and the standard deviation to 4
(startval defaults to 1,2).
fit <- fit.LNB(MS, 20, startval=c(2,4))
It is also recommended to try different start values and observe
whether they arrive at the same parameters.A.5. Bootstrapping the conﬁdence limits
In the previous step, point estimates for completeness were ob-
tained. The provided boot strapping routine obtains the conﬁdence
limits for parameters of interest. First, a set of 100 boot strapping
samples is obtained by:
boot <- boot.CI(MS, 20, noruns=100,
startval=c(1.8,2.2))
The function boot.LNB returns a table with 100 bootstraps and
columns for m, s, D.hat and D.null. The 80% limits for estimated
completeness is obtained via:
quantile(boot D.hat, c(0.1, 0.9), na.rm=TRUE)
Note that due to the fallibility of numerical optimization, a
small number of bootstraps typically fails and NA is returned.A.6. Predicting required sample size
The point estimator for required sample size, say for an 85% tar-
get, is obtained by the logit-normal geometric quantile function:
qlngeom(0.85, fit m, fit s)
The function operates on vectors of estimates, allowing one to
obtain conﬁdence limits from bootstrapping data already obtained:
boot.85 <- qlngeom(0.85, boot m, boot s)
quantile(boot.85, c(0.1,0.9), na.rm=TRUE)
A.7. Diagnostic plots
Plots like those contained in the paper are obtained by combin-
ing the provided functions with the rich built-in plotting capabili-
ties of R. For example, a plot similar to Fig. 2 is obtained by:plot(dlnbinom(c(1:20), 20, fit m, fit s),ylim=c(0,
0.3), t=’’l’’)
points(tabulate(MS)/(fit problem.n + D.null(fit)),t=’h’)
Note, how the estimate for unobserved problems is added to
scale the observed distribution.
The parametric interpolation curve (like in Fig. 4, with an
extrapolation to n = 40) is plotted via:
plot(plngeom(0:40, fit m, fit s))
Appendix B. Supplementary material
Statistical software and example data as demonstrated in
Appendix B can be found, in the online version, at http://
dx.doi.org/10.1016/j.jbi.2013.04.007.
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